Factors influencing mortality in covid-19-associated mucormycosis - the international ID-IRI study
Erişim
info:eu-repo/semantics/closedAccessTarih
2024Yazar
Şahin, MeyhaYılmaz, Mesut
Mert, Ali
Naghili, Behrouz
Ravanbakhsh, Fatemeh
Varshochi, Mojtaba
Alavi Darazam, Ilad
Ebrahimi, Mohammad Javad
Moafi, Maral
Tehrani, Hamed Azhdari
Mahboob, Amjad
Rashid, Naveed
Khan, Ejaz Ahmed
Hakamifard, Atousa
Eser Karlıdağ, Gülden
Babamahmoodi, Abdolreza
El-Kholy, Amani
Mosawi, Sayed Hussain
Albayrak, Ayşe
Wadi Al Ramahi, Jamal
Addepalli, Syam Kumar
Balin, Şafak Özer
Khan, Asfandiyar
Pandya, Nirav
Gürbüz, Esra
Sincan, Gülden
Azami, Hadia
Dumlu, Rıdvan
Khedr, Reham
Ripon, Rezaul Karim
Alkan, Sevil
Köse, Şükran
Ceylan, Bahadır
Erdem, Hakan
Üst veri
Tüm öğe kaydını gösterKünye
Şahin, M., Yılmaz, M., Mert, A., Naghili, B., Ravanbakhsh, F., Varshochi, M. ... Erdem, H. (2024). Factors influencing mortality in covid-19-associated mucormycosis - the international ID-IRI study. Medical Mycology. http://dx.doi.org/10.1093/mmy/myae064Özet
The emergence of COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), triggered a global pandemic. Concurrently, reports of mucormycosis cases surged, particularly during the second wave in India. This study aims to investigate mortality factors in COVID-19-associated mucormycosis (CAM) cases, exploring clinical, demographic, and therapeutic variables across mostly Asian and partly African countries. A retrospective, cross-sectional analysis of CAM patients from 22 medical centers across eight countries was conducted, focusing on the first three months post-COVID-19 diagnosis. Data collected through the IDI-IR included demographics, comorbidities, treatments, and outcomes. A total of 162 CAM patients were included. The mean age was 54.29±13.04 years, with 54% male. Diabetes mellitus (85%) was prevalent, and 91% had rhino-orbital-cerebral mucormycosis (ROCM). Surgical debridement was performed in 84% of the cases. Mortality was 39%, with advanced age [Hazard Ratio (HR)=1.06, (p<0.001)], rituximab use (HR=21.2, p=0.05), diabetic ketoacidosis (HR=3.58, p=0.009) identified as risk factors. The mortality risk increases by approximately 5.6% for each additional year of age. Surgical debridement based on organ involvement correlated with higher survival (HR=8.81, p<0.001). The utilization of rituximab and diabetic ketoacidosis along with advancing age, has been associated with an increased risk of mortality in CAM patients. A combination of antifungal treatment and surgical intervention has demonstrated a substantial improvement in survival outcomes.
Kaynak
Medical MycologyKoleksiyonlar
- Makale Koleksiyonu [3760]
- PubMed İndeksli Yayınlar Koleksiyonu [4214]